ConoGenetix biosciences

About:

ConoGenetix biosciences is a biotechnology company that focuses on the development of peptide-based drugs.

Website: http://www.conogenetix.de/

Top Investors: BioM AG, Mey Capital Matrix

Description:

conoGenetix is a privately owned biopharmaceutical company focused on the development of new peptide therapeutics for the treatment of autoimmune diseases. conoGenetix was founded in 2002 by Dr. Andreas Klostermann and Dr. Jörg Stockhaus and is located in Martinsried, Germany. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets causatively involved in the generation of autoimmune diseases. conoGenetix runs a program targeting severe autoimmune disorders like Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Several peptides called cgtx-peptides within this program are in preclinical development. The leading indication for the cgtx-peptides will be Vasculitis; a fatal disease strongly related to Rheumatoid Arthritis. Vasculitis is a rare disease and will be a market door opener for conoGenetix.